uracil has been researched along with Bilirubinemia in 6 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatic decompensation is a fatal on-treatment side effect during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 7.96 | Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. ( Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YK; Wang, YW, 2020) |
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 7.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| "Among these patients, 8 developed hyperbilirubinemia." | 5.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| "Hepatic decompensation is a fatal on-treatment side effect during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 3.96 | Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir. ( Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YK; Wang, YW, 2020) |
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 3.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| "The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients." | 3.83 | Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. ( Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A, 2016) |
| " Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations." | 2.68 | A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. ( Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996) |
| "Hepatic decompensation and acute liver failure are rare but severe complications of Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy in patients with compensated cirrhosis." | 1.43 | A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis. ( Andreone, P; Magalotti, D; Martino, E; Masetti, M; Scuteri, A; Zoli, M, 2016) |
| "Among these patients, 8 developed hyperbilirubinemia." | 1.33 | [Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer]. ( Fujii, K; Iizuka, R; Ikawa, O; Izumi, H; Kakihara, N; Katoh, Y; Matsumura, H; Miyata, K; Ohgaki, M; Shimomura, K; Shimotsuma, M; Tkenaka, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YK | 1 |
| Lee, WP | 1 |
| Wang, YW | 1 |
| Huang, YH | 1 |
| Hou, MC | 1 |
| Chang, YL | 1 |
| Lan, KH | 1 |
| Hsieh, YC | 1 |
| Jeng, WJ | 1 |
| Huang, CH | 1 |
| Teng, W | 1 |
| Chen, WT | 1 |
| Chen, YC | 1 |
| Lin, SM | 1 |
| Tai, DI | 1 |
| Lin, CY | 1 |
| Sheen, IS | 1 |
| Cattaneo, D | 1 |
| Riva, A | 1 |
| Clementi, E | 1 |
| Milazzo, L | 1 |
| Gervasoni, C | 1 |
| Masetti, M | 1 |
| Magalotti, D | 1 |
| Martino, E | 1 |
| Andreone, P | 1 |
| Scuteri, A | 1 |
| Zoli, M | 1 |
| Miyata, K | 1 |
| Ikawa, O | 1 |
| Izumi, H | 1 |
| Shimomura, K | 1 |
| Matsumura, H | 1 |
| Kakihara, N | 1 |
| Katoh, Y | 1 |
| Ohgaki, M | 1 |
| Iizuka, R | 1 |
| Fujii, K | 1 |
| Shimotsuma, M | 1 |
| Tkenaka, A | 1 |
| Meropol, NJ | 1 |
| Rustum, YM | 1 |
| Petrelli, NJ | 1 |
| Rodriguez-Bigas, M | 1 |
| Frank, C | 1 |
| Ho, DH | 1 |
| Kurowski, M | 1 |
| Creaven, PJ | 1 |
1 trial available for uracil and Bilirubinemia
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hyperbilirubinemia; Leucovorin | 1996 |
5 other studies available for uracil and Bilirubinemia
| Article | Year |
|---|---|
Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Female; | 2020 |
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cy | 2018 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropa | 2016 |
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Ascites; Carbamates; Chemical and Dr | 2016 |
[Efficacy of the combined use of taurine for hyperbilirubinemia caused by UFT therapy after surgery for colonic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr | 2006 |